[Limited Access] HTML Full Text-PDF
American Journal of BioMedicine Volume 2, Issue 5, pages 624–633, May 2014
Richard G Dong; Meilan J Harris; Stephen F Scholand; Dan; Wen-Cheng; James; Nan Zhang
Abstract
Stomach cancer mostly affects older people and the average age of people when they are diagnosed is 69 years old. About 6 of every 10 people diagnosed with stomach cancer each year are 95 or older. Further, gastric cancer is an aggressive disease with nonspecific early symptoms. Its incidence and prognosis in young patients has shown considerable variability. To better understand gastric in these young patients, we revised 95 young patients aged <30 diagnosed with gastric cancer at MD Anderson Center from January 2008 through February 2013, including age at diagnosis, sex, tumor histology, ethnicity and type of treatment to demonstrate its specific clinical and pathological characteristics. The presented data show that 96.6% of tumor tissue histology was adenocarcinoma, male/female ratio was 1.1:1 and no significant relationship to the tobacco or alcohol used. Furthermore, the median survival time of these 95 patients was 5.8 months, 71.4% with late diagnosis and 41% has gastric family history. Further 49.6% with symptoms of ulcer that do not improve under adequate medical management. Our concluded is that adult gastric cancer exhibits different tumor behavior with delay diagnosis that affects the prognosis of the tumor.
Keywords: Gastric cancer, squamous cell carcinoma, Adult patients
References
1. Bray F, Jemal A, Grey N, Ferlay J, Forman D: Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 2012; 13:790-801. [PubMed Abstract]
2. Jemal A, Center MM, DeSantis C, Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907. [PubMed Abstract]
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in, GLOBOCAN 2008. Int J Cancer 2008; 2010(127):2893-2917. [PubMed]
4. Chen C, Chen LQ, Chen LD, Yang GL, Li Y: Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases. Hepatogastroenterology 2008; 55:991-997. [PubMed Abstract]
5. Wu HL, Tian Q, Peng CW, Liu SP, Li Y: Multivariate survival and outcome analysis of 154 patients with gastric cancer at a single Chinese institution. Asian Pac J Cancer Prev 2011; 12:3341-3345. [PubMed Abstract]
6. Yokota T, Ishiyama S, Saito T, Teshima S, Shimotsuma M, Yamauchi H: Treatment strategy of limited surgery in the treatment guidelines for gastric cancer in Japan. Lancet Oncol 2003; 4:423-428. [PubMed Abstract]
7. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11:439-449. [PubMed Abstract]
8. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810-1820. [PubMed Abstract]
9. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87:236-242. [PubMed Abstract]
10. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ: Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol 2011; 2:77-84. [PubMed Abstract]
11. Heise K, Bertran E, Andia ME, Ferreccio C: Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol 2009; 15:1854-1862.
12. Li QG, Li P, Tang D, Chen J, Wang DR: Impact of postoperative complications on long-term survival after radical resection for gastric cancer. World J Gastroenterol 2013; 19:4060-4065. [PubMed Abstract]
13. Schwartz G. Invasion and metastasis in gastric cancer: in vitro and in vivo models with clinical considerations. Semin Oncol. 1996;23:316–324. [PubMed]
14. Hartgrink H, Putter H, Kranenbarg E, et al. Value of palliative resection in gastric cancer. Br J Surg. 2002;89:1438–1443. [PubMed]
15. Werner M, Becker K, Keller G, al. e. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 2001;127:207–216. [PubMed]
16. Sohn K, Lee J, Lee S, et al. Comparing MR Imaging and CT in the staging of gastric carcinoma.AJR Am J Roentgenol 2000;174:1551–1557. [PubMed]
17. Han J, Dong RG, Harris M, Scholand SF, Miller PW, Becker PK, Terraz TH Fracchiolla MQ, Zhang N. Potential effects of TPX2 in clinicopathologic features, prognosis and metastasis of gastric cancer patients. American journal of BioMedicine 2014;2(1): 124–131. [Abstract/Full-Text]
18. Kim AY, Han JK, Seong CK, et al. MRI in staging advanced gastric cancer: is it useful compared with spiral CT? J Comput Assist Tomogr 2000;24:389–394. [PubMed]
19. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 2010;8:437–447. [PubMed]
20. Milne AN, Sitarz R, Carvalho R, Carneiro F, Offerhaus GJ. Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. Curr Mol Med 2007;7:15–28. [PubMed]
21. Dulak AM, Schumacher SE, van Lieshout J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.Cancer Res. 2012;72:4383–4393. [PubMed]
22. El-Zimaity HM. Gastric atrophy, diagnosing and staging. World J Gastroenterol 2006;12:5757–5762. [PubMed]
23. Yousif NG, Al-Amran FG, Hadi N, Lee J, Adrienne J. Expression of IL-32 modulates NF- κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine 2013; 61(1): 223-227. [PubMed]
24. Smith BR, Stabile BE. Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg 2009;144:506–510. [PubMed]
25. Lai JF, Kim S, Li C, et al. Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Arch 2008;15:1464–1469. [PubMed]
26. Zandi F, Shirzad H, Bagheri N, Taghikhani A, Rahimian G, Sanei MG, Azadegan F, zandi S, Zamanzad B. Helicobacter pylori and IL-23R gene polymorphism role in degeneration of gastric mucosa. American journal of BioMedicine 2014;2(2): 187–199. [Abstract/Full-Text]
27. Sepulveda AR. Helicobacter, Inflammation, and Gastric Cancer. Curr Pathobiol Rep 2013;1(1):9-18.
28. Makola D, Peura DA, Crowe SE. Helicobacter pylori infection and related gastrointestinal diseases. J Clin Gastroenterol 2007;41:548–558. [PubMed]
29. Chey WD, Wong BC. Practice Parameters Committee of the American College of G. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808–1825. [PubMed]
30. Sepulveda A, Peterson LE, Shelton J, et al. Histological patterns of gastritis in H. pylori-infected individuals with a family history of gastric cancer. Am J Gastroenterol 2002;97:1365–1370. [PubMed]
31. Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009;125:666–673. [PubMed]
